Galderma Group AG/Fr. GALD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Galderma Group AG
Galderma Group AG is a global dermatology company specializing in the research, development, and marketing of medical solutions in skin health. The company operates in the pharmaceuticals, medical devices, and consumer products segments, offering treatments for conditions like acne, rosacea, psoriasis, and other dermatological ailments. Founded in 1981 and headquartered in Lausanne, Switzerland, Galderma leverages an extensive global network to distribute its products across various regions. The company's strategic focus on dermatology enables it to maintain a robust portfolio of targeted therapies and skincare solutions that address both medical and aesthetic needs.
- Ticker
- Fr. GALD
- Sector
- Health
- Primary listing
- XSWX
- Employees
- 7,676
- Headquarters
- Zug, Switzerland
- Website
- www.galderma.com
GALD Metrics
BasicAdvanced
CHF 44B
63.09
CHF 3.00
-0.11
CHF 0.35
0.18%
Price and volume
Market cap
CHF 44B
Beta
-0.11
52-week high
CHF 193.90
52-week low
CHF 136.30
Average daily volume
797K
Dividend rate
CHF 0.35
Financial strength
Current ratio
1.242
Quick ratio
0.903
Long term debt to equity
0.323
Total debt to equity
0.331
Dividend payout ratio (TTM)
12.05%
Interest coverage (TTM)
7.34%
Profitability
EBITDA (TTM)
1,139.569
Gross margin (TTM)
69.37%
Net profit margin (TTM)
14.57%
Operating margin (TTM)
19.10%
Effective tax rate (TTM)
8.29%
Revenue per employee (TTM)
CHF 633,090
Management effectiveness
Return on assets (TTM)
5.35%
Return on equity (TTM)
10.82%
Valuation
Price to earnings (TTM)
63.087
Price to revenue (TTM)
9.108
Price to book
5.38
Price to tangible book (TTM)
-30.83
Price to free cash flow (TTM)
50.845
Free cash flow yield (TTM)
1.97%
Free cash flow per share (TTM)
3.726
Dividend yield (TTM)
0.18%
Growth
Revenue change (TTM)
26.29%
Earnings per share change (TTM)
129.78%
What the Analysts think about GALD
Analyst ratings (Buy, Hold, Sell) for Galderma Group AG stock.
Analyst projections of the future price of Galderma Group AG stock.
Bulls say / Bears say
Galderma delivered 25.1% constant-currency sales growth in the first nine months, with double-digit growth in all three product categories, and raised its 2026 sales-growth outlook to 22.5–23.5%. (Galderma)
Profitability is improving alongside sales: first-half core EBITDA rose 42.8% at constant currency and the core EBITDA margin expanded by 328 basis points to 25.6%. (Galderma)
The US launch of Relfydess remains delayed: after FDA manufacturing-site and analytical-method observations, Galderma is targeting a first-quarter 2027 resubmission, postponing a potential growth driver in aesthetics. (Galderma, The Wall Street Journal)
Nemluvio’s growth is concentrated in the US, where it had 5% of paid prescriptions in atopic dermatitis in September–October and faces established competition from Dupixent, which generated €5.2 billion in second-quarter sales. That makes continued share gains important to sustaining the drug’s growth. (Galderma, Fierce Pharma)
A high valuation leaves less room for setbacks: a Swiss market analysis put Galderma at about 33 times forecast 2026 EBITDA and said Nemluvio’s uncertain peak-sales potential is already reflected in expectations. (The Market)
Data summarised monthly by Lightyear AI. Last updated on 22 Oct 2026.
GALD Financial Performance
Revenues and expenses
GALD Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing GALD
AllEURUSDGBP
Fund name | Fund size | Fr. GALD weighting |
|---|---|---|
iShares MSCI Europe Health Care Sector€ESIH | €890M | 2.18% |
iShares MSCI Europe Health Care Sector£ESIH | €890M | 2.18% |
iShares STOXX Europe 600 Health Care€EXV4 | €709M | 2.15% |
HSBC MSCI Europe Islamic Screened$HIEU | €144M | 1.38% |
HSBC MSCI Europe Islamic Screened£HIPS | €144M | 1.38% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.